Skip to main content

Advertisement

SpringerLink
Log in

Angiotensin receptor–neprilysin inhibitors for hypertension—hemodynamic effects and relevance to hypertensive heart disease

  • Review Article
  • Special Issue: Current evidence and perspectives for hypertension management in Asia
  • Published:
Hypertension Research Submit manuscript

Abstract

Angiotensin receptor–neprilysin inhibitors have multiple beneficial effects on the cardiovascular system. The angiotensin receptor–neprilysin inhibitor sacubitril/valsartan has been shown to effectively reduce ambulatory 24-h blood pressure in patients with hypertension, and improvements in many aspects of hemodynamic function have also been reported. Overall hemodynamic effects on arterial stiffness and nocturnal blood pressure play an important role in the pathogenesis of hypertensive heart disease. Therefore, these could represent mechanistic targets underlying the effects of angiotensin receptor–neprilysin inhibitors on the continuum of cardiovascular disease from hypertension to heart failure. Other potential mechanisms include reductions in circulating volume and sympathetic activity, both of which contribute to the protection against target organ damage and positive changes in cardiac biomarkers seen during angiotensin receptor–neprilysin inhibitor therapy. The mechanisms of action and beneficial effects of angiotensin receptor–neprilysin inhibitors are complementary to those of a number of other treatment options for hypertension, suggesting the possibility of additive or even synergistic benefits. Based on available data, there are a number of patient groups who will benefit from antihypertensive treatment with an angiotensin receptor–neprilysin inhibitor, including those with salt-sensitive hypertension, structural hypertension, resistant hypertension, and hypertension in the presence of heart failure. Overall, angiotensin receptor–neprilysin inhibitors regulate blood pressure and pulse pressure via multiple mechanisms and provide cardiovascular protection. This provides an option for effective intervention early in the vicious cycle of elevated blood pressure and central pressures with progression toward heart failure that should help to address the growing worldwide heart failure epidemic.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Yamamoto K, Rakugi H. Angiotensin receptor-neprilysin inhibitors: comprehensive review and implications in hypertension treatment. Hypertens Res. 2021. https://doi.org/10.1038/s41440-41021-00706-41441.

  2. Bavishi C, Messerli FH, Kadosh B, Ruilope LM, Kario K. Role of neprilysin inhibitor combinations in hypertension: insights from hypertension and heart failure trials. Eur Heart J. 2015;36:1967–73.

    Article  CAS  PubMed  Google Scholar 

  3. Ruilope LM, Dukat A, Böhm M, Lacourcière Y, Gong J, Lefkowitz MP. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet. 2010;375:1255–66.

    Article  CAS  PubMed  Google Scholar 

  4. Kario K, Sun N, Chiang FT, Supasyndh O, Baek SH, Inubushi-Molessa A, et al. Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study. Hypertension. 2014;63:698–705.

    Article  CAS  PubMed  Google Scholar 

  5. Williams B, Cockcroft JR, Kario K, Zappe DH, Brunel PC, Wang Q, et al. Effects of sacubitril/valsartan versus olmesartan on central hemodynamics in the elderly with systolic hypertension: the PARAMETER Study. Hypertension. 2017;69:411–20.

    Article  CAS  PubMed  Google Scholar 

  6. Schmieder RE, Wagner F, Mayr M, Delles C, Ott C, Keicher C, et al. The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study. Eur Heart J. 2017;38:3308–17.

    Article  CAS  PubMed  Google Scholar 

  7. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004.

    Article  PubMed  Google Scholar 

  8. Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381:1609–20.

    Article  CAS  PubMed  Google Scholar 

  9. De Vecchis R, Soreca S, Ariano C. Anti-hypertensive effect of sacubitril/valsartan: a meta-analysis of randomized controlled trials. Cardiol Res. 2019;10:24–33.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Li Q, Li L, Wang F, Zhang W, Guo Y, Wang F, et al. Effect and safety of LCZ696 in the treatment of hypertension: a meta-analysis of 9 RCT studies. Medicine. 2019;98:e16093.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Geng Q, Yan R, Wang Z, Hou F. Effects of LCZ696 (sacubitril/valsartan) on blood pressure in patients with hypertension: a meta-analysis of randomized controlled trials. Cardiology. 2020;145:589–98.

    Article  CAS  PubMed  Google Scholar 

  12. Rakugi H, Kario K, Yamaguchi M, Sasajima T, Goutou H, Zhang J. Efficacy of sacubitril/valsartan versus olmesartan in Japanese patients with essential hypertension: a randomized, double-blind, multicenter study. Hypertens Res. 2022;45:824–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Supasyndh O, Sun N, Kario K, Hafeez K, Zhang J. Long-term (52-week) safety and efficacy of Sacubitril/valsartan in Asian patients with hypertension. Hypertens Res. 2017;40:472–6.

    Article  CAS  PubMed  Google Scholar 

  14. Kario K, Tamaki Y, Okino N, Gotou H, Zhu M, Zhang J. LCZ696, a first-in-class angiotensin receptor-neprilysin inhibitor: the first clinical experience in patients with severe hypertension. J Clin Hypertens. 2016;18:308–14.

    Article  CAS  Google Scholar 

  15. Cheung DG, Aizenberg D, Gorbunov V, Hafeez K, Chen CW, Zhang J. Efficacy and safety of sacubitril/valsartan in patients with essential hypertension uncontrolled by olmesartan: a randomized, double-blind, 8-week study. J Clin Hypertens. 2018;20:150–8.

    Article  CAS  Google Scholar 

  16. Huo Y, Li W, Webb R, Zhao L, Wang Q, Guo W. Efficacy and safety of sacubitril/valsartan compared with olmesartan in Asian patients with essential hypertension: a randomized, double-blind, 8-week study. J Clin Hypertens. 2019;21:67–76.

    CAS  Google Scholar 

  17. Izzo JL Jr., Zappe DH, Jia Y, Hafeez K, Zhang J. Efficacy and safety of crystalline valsartan/sacubitril (LCZ696) compared with placebo and combinations of free valsartan and sacubitril in patients with systolic hypertension: the RATIO study. J Cardiovasc Pharmacol. 2017;69:374–81.

    Article  CAS  PubMed  Google Scholar 

  18. Supasyndh O, Wang J, Hafeez K, Zhang Y, Zhang J, Rakugi H. Efficacy and safety of sacubitril/valsartan (LCZ696) compared with olmesartan in elderly asian patients (≥65 Years) with systolic hypertension. Am J Hypertens. 2017;30:1163–9.

    Article  CAS  PubMed  Google Scholar 

  19. Wang TD, Tan RS, Lee HY, Ihm SH, Rhee MY, Tomlinson B, et al. Effects of sacubitril/valsartan (LCZ696) on natriuresis, diuresis, blood pressures, and NT-proBNP in salt-sensitive hypertension. Hypertension. 2017;69:32–41.

    Article  CAS  PubMed  Google Scholar 

  20. Wang JG, Yukisada K, Sibulo A Jr., Hafeez K, Jia Y, Zhang J. Efficacy and safety of sacubitril/valsartan (LCZ696) add-on to amlodipine in Asian patients with systolic hypertension uncontrolled with amlodipine monotherapy. J Hypertens. 2017;35:877–85.

    Article  CAS  PubMed  Google Scholar 

  21. Ito S, Satoh M, Tamaki Y, Gotou H, Charney A, Okino N, et al. Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction. Hypertens Res. 2015;38:269–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Cunningham JW, Vaduganathan M, Claggett BL, Zile MR, Anand IS, Packer M, et al. Effects of sacubitril/valsartan on N-Terminal Pro-B-Type natriuretic peptide in heart failure with preserved ejection fraction. JACC Heart Fail. 2020;8:372–81.

    Article  PubMed  Google Scholar 

  23. Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012;380:1387–95.

    Article  CAS  PubMed  Google Scholar 

  24. Jhund PS, Claggett BL, Voors AA, Zile MR, Packer M, Pieske BM, et al. Elevation in high-sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor LCZ696. Circ Heart Fail. 2014;7:953–9.

    Article  CAS  PubMed  Google Scholar 

  25. Cunningham JW, Claggett BL, O’Meara E, Prescott MF, Pfeffer MA, Shah SJ, et al. Effect of sacubitril/valsartan on biomarkers of extracellular matrix regulation in patients with HFpEF. J Am Coll Cardiol. 2020;76:503–14.

    Article  CAS  PubMed  Google Scholar 

  26. Selvaraj S, Claggett BL, Pfeffer MA, Desai AS, Mc Causland FR, McGrath MM, et al. Serum uric acid, influence of sacubitril-valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HF. Eur J Heart Fail. 2020;22:2093–101.

    Article  CAS  PubMed  Google Scholar 

  27. Jering KS, Zannad F, Claggett B, Mc Causland FR, Ferreira JP, Desai A, et al. Cardiovascular and renal outcomes of mineralocorticoid receptor antagonist use in PARAGON-HF. JACC Heart Fail. 2021;9:13–24.

    Article  PubMed  Google Scholar 

  28. McCausland FR, Lefkowitz MP, Claggett B, Anavekar NS, Senni M, Gori M, et al. Angiotensin-neprilysin inhibition and renal outcomes in heart failure with preserved ejection fraction. Circulation. 2020;142:1236–45.

    Article  CAS  Google Scholar 

  29. McMurray JJ. Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances. Eur J Heart Fail. 2015;17:242–7.

    Article  CAS  PubMed  Google Scholar 

  30. Gu J, Noe A, Chandra P, Al-Fayoumi S, Ligueros-Saylan M, Sarangapani R, et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol. 2010;50:401–14.

    Article  CAS  PubMed  Google Scholar 

  31. Kario K, Williams B. Nocturnal hypertension and heart failure: mechanisms, evidence, and new treatments. Hypertension. 2021;78:564–77.

    Article  CAS  PubMed  Google Scholar 

  32. Kario K. The sacubitril/valsartan, a first-in-class, angiotensin receptor neprilysin inhibitor (ARNI): potential uses in hypertension, heart failure, and beyond. Curr Cardiol Rep. 2018;20:5.

    Article  PubMed  Google Scholar 

  33. Safar ME, Asmar R, Benetos A, Blacher J, Boutouyrie P, Lacolley P, et al. Interaction between hypertension and arterial stiffness. Hypertension. 2018;72:796–805.

    Article  CAS  PubMed  Google Scholar 

  34. Urschel CW, Covell JW, Sonnenblick EH, Ross J Jr., Braunwald E. Effects of decreased aortic compliance on performance of the left ventricle. Am J Physiol. 1968;214:298–304.

    Article  CAS  PubMed  Google Scholar 

  35. Mottram PM, Haluska BA, Leano R, Carlier S, Case C, Marwick TH. Relation of arterial stiffness to diastolic dysfunction in hypertensive heart disease. Heart. 2005;91:1551–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Kelly RP, Tunin R, Kass DA. Effect of reduced aortic compliance on cardiac efficiency and contractile function of in situ canine left ventricle. Circ Res. 1992;71:490–502.

    Article  CAS  PubMed  Google Scholar 

  37. Roman MJ, Devereux RB, Kizer JR, Lee ET, Galloway JM, Ali T, et al. Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart Study. Hypertension. 2007;50:197–203.

    Article  CAS  PubMed  Google Scholar 

  38. Muiesan ML, Salvetti M, Monteduro C, Bonzi B, Paini A, Viola S, et al. Left ventricular concentric geometry during treatment adversely affects cardiovascular prognosis in hypertensive patients. Hypertension. 2004;43:731–8.

    Article  CAS  PubMed  Google Scholar 

  39. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med. 1991;114:345–52.

    Article  CAS  PubMed  Google Scholar 

  40. Sethi S, Rivera O, Oliveros R, Chilton R. Aortic stiffness: pathophysiology, clinical implications, and approach to treatment. Integr Blood Press Control. 2014;7:29–34.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Zhang W, Liu J, Fu Y, Ji H, Fang Z, Zhou W, et al. Sacubitril/valsartan reduces fibrosis and alleviates high-salt diet-induced HFpEF in rats. Front Pharmacol. 2020;11:600953.

    Article  CAS  PubMed  Google Scholar 

  42. Kusaka H, Sueta D, Koibuchi N, Hasegawa Y, Nakagawa T, Lin B, et al. LCZ696, angiotensin II receptor-neprilysin inhibitor, ameliorates high-salt-induced hypertension and cardiovascular injury more than valsartan alone. Am J Hypertens. 2015;28:1409–17.

    Article  CAS  PubMed  Google Scholar 

  43. Aroor AR, Mummidi S, Lopez-Alvarenga JC, Das N, Habibi J, Jia G, et al. Sacubitril/valsartan inhibits obesity-associated diastolic dysfunction through suppression of ventricular-vascular stiffness. Cardiovasc Diabetol. 2021;20:80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Suzuki K, Claggett B, Minamisawa M, Nochioka K, Mitchell GF, Anand IS, et al. Pulse pressure, prognosis, and influence of sacubitril/valsartan in heart failure with preserved ejection fraction. Hypertension. 2021;77:546–56.

    Article  CAS  PubMed  Google Scholar 

  45. Desai AS, Solomon SD, Shah AM, Claggett BL, Fang JC, Izzo J, et al. Effect of sacubitril-valsartan vs enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: a randomized clinical trial. JAMA. 2019;322:1077–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Hartupee J, Mann DL. Neurohormonal activation in heart failure with reduced ejection fraction. Nat Rev Cardiol. 2017;14:30–8.

    Article  CAS  PubMed  Google Scholar 

  47. Sayer G, Kalantari S, Tayazime S, Dedvedofsky D, Kim G, Sarswat N, et al. Reduction of sympathetic innervation following transition to sacubutril/valsartan in the REMODEL (Reverse Remodeling Effects of Entresto) study. J Card Fail. 2018;24:S32.

    Article  Google Scholar 

  48. Volpe M, Cuocolo A, Vecchione F, Mele AF, Condorelli M, Trimarco B. Vagal mediation of the effects of atrial natriuretic factor on blood pressure and arterial baroreflexes in the rabbit. Circ Res. 1987;60:747–55.

    Article  CAS  PubMed  Google Scholar 

  49. Polhemus DJ, Trivedi RK, Gao J, Li Z, Scarborough AL, Goodchild TT, et al. Renal sympathetic denervation protects the failing heart via inhibition of neprilysin activity in the kidney. J Am Coll Cardiol. 2017;70:2139–53.

    Article  PubMed  Google Scholar 

  50. Pascual-Figal DA. Neprilysin and heart failure: a “sympathetic” relationship? J Am Coll Cardiol. 2017;70:2154–6.

    Article  PubMed  Google Scholar 

  51. Guyton AC. Blood pressure control–special role of the kidneys and body fluids. Science. 1991;252:1813–6.

    Article  CAS  PubMed  Google Scholar 

  52. Uzu T, Ishikawa K, Fujii T, Nakamura S, Inenaga T, Kimura G. Sodium restriction shifts circadian rhythm of blood pressure from nondipper to dipper in essential hypertension. Circulation. 1997;96:1859–62.

    Article  CAS  PubMed  Google Scholar 

  53. Vardeny O, Claggett B, Kachadourian J, Desai AS, Packer M, Rouleau J, et al. Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trial. Eur J Heart Fail. 2019;21:337–41.

    Article  CAS  PubMed  Google Scholar 

  54. Ter Maaten JM. Unravelling the effect of sacubitril/valsartan on loop diuretic dosing. Eur J Heart Fail. 2019;21:342–4.

    Article  PubMed  Google Scholar 

  55. Vaduganathan M, Claggett BL, Jhund PS, Cunningham JW, Pedro Ferreira J, Zannad F, et al. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet. 2020;396:121–8.

    Article  CAS  PubMed  Google Scholar 

  56. Lin DS, Wang TD, Buranakitjaroen P, Chen CH, Cheng HM, Chia YC, et al. Angiotensin receptor neprilysin inhibitor as a novel antihypertensive drug: evidence from Asia and around the globe. J Clin Hypertens. 2021;23:556–67.

    Article  CAS  Google Scholar 

  57. Lin DS-H, Wang T-D, Buranakitjaroen P, Chen C-H, Cheng H-M, Chia YC, et al. Network tHA. Angiotensin receptor neprilysin inhibitor as a novel antihypertensive drug: evidence from Asia and around the globe. J Clin Hypertens. 2021;23:556–67.

    Article  CAS  Google Scholar 

  58. Kario K, Hoshide S, Mizuno H, Kabutoya T, Nishizawa M, Yoshida T, et al. Nighttime blood pressure phenotype and cardiovascular prognosis: practitioner-based nationwide JAMP study. Circulation. 2020;142:1810–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Hoshide S, Kanegae H, Kario K. Nighttime home blood pressure as a mediator of N-terminal pro-brain natriuretic peptide in cardiovascular events. Hypertens Res. 2021;44:1138–46.

    Article  CAS  PubMed  Google Scholar 

  60. Kario K, Hoshide S, Nagai M, Okawara Y, Kanegae H. Sleep and cardiovascular outcome in relation to nocturnal hypertension: the J-HOP Nocturnal Blood Pressure study. Hypertens Res. 2021;44:1589–96.

  61. Narita K, Hoshide S, Kario K. Difference between morning and evening home blood pressure and cardiovascular events. The J-HOP study (Japan Morning Surge-Home Blood Pressure). Hypertens Res. 2021;44:1597–605.

  62. Carey RM, Calhoun DA, Bakris GL, Brook RD, Daugherty SL, Dennison-Himmelfarb CR, et al. Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association. Hypertension. 2018;72:e53–e90.

    Article  CAS  PubMed  Google Scholar 

  63. Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019). Hypertens Res. 2019;42:1235–481.

    Article  PubMed  Google Scholar 

  64. Whelton PK, Carey RM, Aronow WS, Casey DE Jr., Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2018;138:e426–83.

    PubMed  Google Scholar 

  65. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021–104.

    Article  PubMed  Google Scholar 

  66. Williams B, MacDonald TM, Morant SV, Webb DJ, Sever P, McInnes GT, et al. Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. Lancet Diabetes Endocrinol. 2018;6:464–75.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Januzzi JL Jr., Prescott MF, Butler J, Felker GM, Maisel AS, McCague K, et al. Association of change in N-terminal Pro-B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction. JAMA. 2019;322:1085–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. McMurray JJ, Carson PE, Komajda M, McKelvie R, Zile MR, Ptaszynska A, et al. Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. Eur J Heart Fail. 2008;10:149–56.

    Article  PubMed  Google Scholar 

  69. de Diego C, González-Torres L, Núñez JM, Centurión Inda R, Martin-Langerwerf DA, Sangio AD, et al. Effects of angiotensin-neprilysin inhibition compared to angiotensin inhibition on ventricular arrhythmias in reduced ejection fraction patients under continuous remote monitoring of implantable defibrillator devices. Heart Rhythm. 2018;15:395–402.

    Article  PubMed  Google Scholar 

  70. Curtain JP, Jackson AM, Shen L, Jhund PS, Docherty KF, Petrie MC, et al. Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in PARADIGM-HF. Eur J Heart Fail. 2022;24:551–61.

    Article  CAS  PubMed  Google Scholar 

  71. Wang Q, Zhuo C, Xia Q, Jiang J, Wu B, Zhou D, et al. Sacubitril/valsartan can reduce atrial fibrillation recurrence after catheter ablation in patients with persistent atrial fibrillation. Cardiovasc Drugs Ther. 2022, in press.

  72. Liu X, Liu H, Wang L, Zhang L, Xu Q. Role of sacubitril-valsartan in the prevention of atrial fibrillation occurrence in patients with heart failure: A systematic review and meta-analysis of randomized controlled trials. PLoS ONE. 2022;17:e0263131.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Tsutsui H, Momomura SI, Saito Y, Ito H, Yamamoto K, Sakata Y, et al. Efficacy and safety of sacubitril/valsartan in Japanese patients with chronic heart failure and reduced ejection fraction- results from the PARALLEL-HF study. Circ J. 2021;85:584–94.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

Medical writing assistance was provided by Nicola Ryan, an independent medical writer, and was funded by Jichi Medical University.

Author information

Authors and Affiliations

  1. Jichi Medical University School of Medicine, Tochigi, Japan

    Kazuomi Kario

  2. Institute of Cardiovascular Science, University College London and National Institute for Health Research, University College London Hospitals Biomedical Research Centre, London, UK

    Bryan Williams

Authors
  1. Kazuomi Kario
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bryan Williams
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kazuomi Kario.

Ethics declarations

Conflict of interest

KK has received honoraria from Novartis outside the submitted work and acts as an editor-in-chief of Hypertension Research (an official journal of the Japanese Society of Hypertension) and a vice president of the Japanese Society of Hypertension. BW has received honoraria from Novartis and acts as Secretary in the International Society of Hypertension.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kario, K., Williams, B. Angiotensin receptor–neprilysin inhibitors for hypertension—hemodynamic effects and relevance to hypertensive heart disease. Hypertens Res 45, 1097–1110 (2022). https://doi.org/10.1038/s41440-022-00923-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41440-022-00923-2

  • Springer Nature Singapore Pte Ltd.

Keywords

This article is cited by

Search

Navigation